Barclays analyst Matt Miksic raised the firm’s price target on Tandem Diabetes to $58 from $55 and keeps an Overweight rating on the shares. After a 25% slide in the stock since mid-July, the firm expects the company’s Q2 beat to sales and EBITDA “to drive significant upside in the stock ” The analyst sees the potential for further upward revisions to estimates into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Top Stock Gainers Today – TNDM, TWLO, and More
- Tandem Diabetes price target raised to $39 from $36 at Baird
- Tandem Diabetes sees Q3 revenue $222M-$225M, consensus $220.7M
- Tandem Diabetes raises FY24 revenue to $885M-$892M from $868M, consensus $869.4M
- Tandem Diabetes reports Q2 EPS (47c), consensus (54c)